GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allergy Therapeutics PLC (LSE:AGY) » Definitions » Total Inventories

Allergy Therapeutics (LSE:AGY) Total Inventories : £11.89 Mil (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Allergy Therapeutics Total Inventories?

Allergy Therapeutics's total inventories for the quarter that ended in Dec. 2023 was £11.89 Mil. Allergy Therapeutics's average total inventories from the quarter that ended in Jun. 2023 to the quarter that ended in Dec. 2023 was £11.74 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Allergy Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was £-0.00.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Allergy Therapeutics's Days Inventory for the six months ended in Dec. 2023 was 164.20.

Inventory Turnover measures how fast the company turns over its inventory within a year. Allergy Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 was 1.11.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Allergy Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.35.


Allergy Therapeutics Total Inventories Historical Data

The historical data trend for Allergy Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Total Inventories Chart

Allergy Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.41 10.13 10.84 11.41 11.59

Allergy Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.60 11.41 10.97 11.59 11.89

Allergy Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Allergy Therapeutics  (LSE:AGY) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Allergy Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

Net-Net Working Capital Per Share (Q: Dec. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(13.522+0.75 * 9.934+0.5 * 11.893-42.615
-0-0)/4766.44
=-0.00

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Allergy Therapeutics's Days Inventory for the six months ended in Dec. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=11.743/13.052*365 / 2
=164.20

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Allergy Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2023 ) / Average Total Inventories (Q: Dec. 2023 )
=13.052 / 11.743
=1.11

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Allergy Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=11.743 / 33.572
=0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Allergy Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics (LSE:AGY) Business Description

Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergies with aluminum-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics (LSE:AGY) Headlines

No Headlines